Check-Cap Ltd. (MBAI) 주식 분석

회사 개요

Check-Cap Ltd. is a clinical stage medical diagnostics entity that specializes in developing and commercializing capsule-based screening technology products designed for non-invasive medical testing. The company operates within the Healthcare sector, specifically targeting the Diagnostics & Research industry, which implies a focus on medical devices and analytical procedures used for disease detection and research rather than direct patient care services. As of the latest available data, the company carries a market capitalization of $12.03M, though specific annual revenue figures and employee headcount are not disclosed in the current financial reports. This relatively modest market cap suggests that the company is a small-cap entity with limited public liquidity and likely operates with a lean operational structure typical of early-stage biotech or diagnostic firms. The absence of reported revenue in the trailing twelve-month period indicates that the company is likely still in a development or pre-revenue phase, relying heavily on capital markets for funding to advance its technology through clinical trials. The financial scale defined by a market cap under $15M and negative earnings highlights the high-risk, high-potential nature of clinical stage companies that have not yet achieved commercial product-market fit.

재무 건전성

The company reported a net loss of $-13,624,000 over the trailing twelve months, while its EBITDA stands at $-3,756,500, indicating that the gap between revenue and net income is driven entirely by significant non-operating expenses or one-time charges rather than core operational inefficiencies, given the zero revenue base. Free cash flow for the period was $-1,058,125, which signifies a substantial cash burn rate that consumes the company's liquidity reserves and necessitates continuous access to external financing to sustain operations. All three key margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting the fact that the company has not yet generated revenue streams necessary to calculate meaningful profitability percentages or cost-of-goods-sold efficiencies. The balance sheet shows the company holds $1.42M in cash against a total debt obligation of $139,000, resulting in a Debt to Equity ratio of 3.69, which technically classifies the entity as highly leveraged by standard ratio definitions despite the nominal debt amount, likely due to a tiny equity base. The Current Ratio stands at 0.71, a figure below the standard threshold of 1.0, which indicates that the company's short-term liquid assets are insufficient to cover its current liabilities without relying on new equity issuance or debt refinancing. Return on Equity is reported at -130.1% and Return on Assets at -20.8%, metrics that reveal that management is currently eroding shareholder value and utilizing assets inefficiently in the absence of profitable commercial operations.

밸류에이션 평가

Trailing P/E and Forward P/E ratios are both unavailable (N/A) because the company is currently unprofitable, meaning traditional earnings-based valuation multiples cannot be calculated or do not provide meaningful insight into future earnings trajectory expectations. The Price to Book ratio is 2.57, suggesting that the market is valuing the company at a premium of 157% over its net book value, which often occurs in clinical stage companies where intangible assets like intellectual property and future potential are priced higher than their recorded balance sheet value. Alternative valuation metrics such as Price to Sales and EV/EBITDA are also unavailable or negative (EV/EBITDA is -2.23), indicating that investors are not using cash flow or sales multiples to value the stock in a traditional sense due to the lack of positive operating performance. The stock's 52-week trading range spans from a low of $0.59 to a high of $3.92, providing a wide volatility band that reflects the speculative nature of the investment. Without a specific current price to calculate the exact percentage deviation, the stock's position within this $3.33 range highlights the extreme price sensitivity typical of small-cap healthcare stocks. The Beta of 0.79 indicates that the stock's price volatility is approximately 21% lower than the broader market average, suggesting that despite its high risk profile due to lack of profitability, the stock historically moves less aggressively than the S&P 500 during periods of market turbulence.

Growth & Income

Revenue growth and earnings growth rates are both unavailable (N/A) due to the lack of historical revenue data, making it impossible to determine whether the company is growing faster or slower than a revenue baseline that does not yet exist. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means the firm retains all of its scarce cash reserves to fund research and development rather than distributing income to shareholders. Since the company reinvests all available capital into advancing its capsule-based technology and clinical trials, there is no current income profile for investors to rely upon, and the growth profile is entirely dependent on the successful progression of its clinical stage medical diagnostics products. The overall growth and income profile is characterized by a complete absence of current cash returns and undefined growth rates, requiring investors to assume the risk of capital appreciation based solely on the potential success of future commercialization rather than established financial performance.